News Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-15 EDT			5-day change	1st Jan Change
3.64 ^USD	0.00%		+4.00%	-36.47%

05-09	Truist Adjusts Price Target on Caribou Biosciences to $19 From $21, Maintains Buy Rating	MT
05-07	Caribou Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Caribou Biosciences : Cas12a chRDNA in vivo editing ASGCT 2024	05-10	PU
Truist Adjusts Price Target on Caribou Biosciences to $19 From $21, Maintains Buy Rating	05-09	MT
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update	05-07	AQ
Caribou Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Caribou Biosciences to Participate in Upcoming Investor Conferences	05-01	AQ
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	04-24	AQ
Caribou Biosciences : CB-010 ANTLER Case Study iwCAR-T 2024	04-23	PU
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)	04-15	AQ
Caribou Biosciences : CB-012 IND-enabling preclinical data AACR 2024	04-09	PU
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday	04-05	MT
Caribou Gets FDA Clearance For Phase 1 Testing of CB-010 Cell Therapy in Lupus Patients	04-04	MT
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus	04-04	AQ
Caribou Biosciences, Inc. Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus	04-04	CI
Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer	03-25	MT
HC Wainwright Adjusts Caribou Biosciences Price Target to $24 From $23, Maintains Buy Rating	03-19	MT
Caribou Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-11	CI
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	03-11	AQ
Caribou Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-11	CI
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting	03-05	AQ
Caribou Biosciences to Participate in Upcoming Investor Conferences	02-15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Summary

Filters